Skip to main content
logo
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

COAG Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
Dec '25 Dec '24
Selling, General & Admin
10.498.97
Research & Development
59.6341.41
Operating Expenses
70.1250.38
Operating Income
-70.12-50.38
Interest Expense (Income)
-1.97-3.74
Other Expense (Income)
-4.011.88
Pretax Income
-64.14-48.52
Income Tax
-0.230.19
Net Income
-63.91-48.71
Free Cash Flow
-61.49-45.87
EBITDA
-65.81-52.01
Depreciation & Amortization
0.30.25
EBIT
-66.11-52.26
Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).